Fig. 4From: Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in UgandaPercentage reduction of efavirenz resistant for rilpivirine doravirine and etravirineBack to article page